Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.

Tevimbra is under clinical development by BeiGene and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 47% phase ...

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Serious liver and nonliver outcomes linked to metabolic dysfunction–associated steatotic liver disease were different between ...

The following is a summary of “Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of ...

The following is a summary of “Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small ...

There’s a stigma surrounding liver cancer. Once you tell people you’ve got it, often you sense a slight judgment. “Oh”, you ...